Karleen Marie Oberton Sells 1,023 Shares of Hologic, Inc. (HOLX) Stock

Hologic, Inc. (NASDAQ:HOLX) VP Karleen Marie Oberton sold 1,023 shares of the company’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $39.84, for a total value of $40,756.32. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Karleen Marie Oberton also recently made the following trade(s):

  • On Wednesday, November 8th, Karleen Marie Oberton sold 1,256 shares of Hologic stock. The shares were sold at an average price of $39.29, for a total value of $49,348.24.
  • On Monday, November 6th, Karleen Marie Oberton sold 538 shares of Hologic stock. The shares were sold at an average price of $39.40, for a total value of $21,197.20.

Hologic, Inc. (NASDAQ HOLX) traded up $0.41 during mid-day trading on Tuesday, hitting $40.60. 2,693,622 shares of the stock traded hands, compared to its average volume of 2,737,376. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.61 and a current ratio of 0.79. Hologic, Inc. has a twelve month low of $35.76 and a twelve month high of $46.80. The stock has a market cap of $11,519.41, a price-to-earnings ratio of 19.78, a P/E/G ratio of 1.93 and a beta of 0.93.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.01. Hologic had a net margin of 10.30% and a return on equity of 11.74%. The business had revenue of $802.90 million for the quarter, compared to analyst estimates of $792.54 million. During the same period in the prior year, the company posted $0.52 EPS. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. research analysts expect that Hologic, Inc. will post 2.12 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Karleen Marie Oberton Sells 1,023 Shares of Hologic, Inc. (HOLX) Stock” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://sportsperspectives.com/2017/11/21/karleen-marie-oberton-sells-1023-shares-of-hologic-inc-holx-stock.html.

Several hedge funds have recently bought and sold shares of the company. Stratos Wealth Partners LTD. boosted its stake in shares of Hologic by 0.6% during the 2nd quarter. Stratos Wealth Partners LTD. now owns 4,954 shares of the medical equipment provider’s stock worth $225,000 after acquiring an additional 30 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in shares of Hologic by 0.4% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 20,803 shares of the medical equipment provider’s stock worth $944,000 after acquiring an additional 85 shares in the last quarter. Symphony Asset Management LLC boosted its stake in shares of Hologic by 0.4% during the 2nd quarter. Symphony Asset Management LLC now owns 28,005 shares of the medical equipment provider’s stock worth $1,271,000 after acquiring an additional 108 shares in the last quarter. Cutter & CO Brokerage Inc. boosted its stake in shares of Hologic by 1.7% during the 2nd quarter. Cutter & CO Brokerage Inc. now owns 11,530 shares of the medical equipment provider’s stock worth $523,000 after acquiring an additional 190 shares in the last quarter. Finally, Shell Asset Management Co. boosted its stake in shares of Hologic by 0.8% during the 2nd quarter. Shell Asset Management Co. now owns 24,847 shares of the medical equipment provider’s stock worth $1,128,000 after acquiring an additional 200 shares in the last quarter. 97.72% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts recently issued reports on the company. Zacks Investment Research raised Hologic from a “sell” rating to a “hold” rating in a research report on Tuesday, October 31st. Needham & Company LLC reissued a “buy” rating and issued a $50.00 target price on shares of Hologic in a research report on Friday, November 3rd. BidaskClub downgraded Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Stifel Nicolaus reissued a “buy” rating and issued a $45.00 target price (down from $48.00) on shares of Hologic in a research report on Monday, October 9th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $44.00 target price (down from $49.00) on shares of Hologic in a research report on Tuesday, October 10th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $47.54.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Insider Buying and Selling by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply